April 20 (Reuters) - Alnylam Pharmaceuticals Inc:
* ALNYLAM REACHES SETTLEMENT AGREEMENT WITH DICERNA PHARMACEUTICALS RESOLVING TRADE SECRET MISAPPROPRIATION AND OTHER PENDING LITIGATION
* ALNYLAM PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, DICERNA WILL PAY $25 MILLION COMPRISED OF CASH AND STOCK TO ALNYLAM
* ALNYLAM PHARMACEUTICALS INC - SETTLEMENT DOES NOT INCLUDE ANY LICENSE TO ALNYLAM’S GALNAC CONJUGATE INTELLECTUAL PROPERTY
* ALNYLAM - AS PER SETTLEMENT, DICERNA WILL BE RESTRICTED IN ITS DEVELOPMENT RELATING TO OLIGONUCLEOTIDE-BASED THERAPEUTICS FOR A DEFINED SET OF CO’S TARGETS
* ALNYLAM PHARMACEUTICALS - ALL OTHER SETTLEMENT TERMS ARE CONFIDENTIAL Source text for Eikon: Further company coverage: